Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

This joint consensus statement from several Polish professional associations discusses strategies for improving obesity treatment and enhancing primary care's role in managing obesity, with no new empirical data reported.

This study describes the patterns of clinical response in patients with severe alopecia areata treated with baricitinib over 52 weeks, based on integrated data from two Phase 3 trials.

This article highlights disparities in the prevalence of alopecia areata among people with skin of color and suggests this information could help dermatologic providers address challenges in treating this population.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

This study found that oral baricitinib treatment led to hair regrowth in patients with alopecia areata, as observed in two phase 3 trials.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study found that women with lower hair loss six months after bariatric surgery consumed more zinc and iron and showed less compromise in the nutritional status of these minerals compared to women with more significant hair loss.

The authors describe a case where a 24-year-old woman experienced diffuse hair loss, likely telogen effluvium, after bariatric surgery, suggesting nutritional deficiencies and multifactorial causes may contribute to this condition.

In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.

This pilot study observed that post-bariatric surgery, both zinc and iron deficiencies increased among Iraqi patients, underscoring the importance of lifelong nutritional monitoring and targeted supplementation to address these issues and prevent related complications.

This study found that only a small percentage of alopecia areata patients treated with baricitinib in real-world settings would have met the eligibility criteria used in clinical trials.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study found that in patients with severe alopecia areata, those who responded early to baricitinib treatment typically had a lower baseline Severity of Alopecia Tool score, shorter disease duration, and higher erythrocyte sedimentation rate, suggesting these factors may predict therapeutic success.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

This study examined three olive oil formulations of baricitinib for topical delivery in treating alopecia areata, finding that Oil A showed the highest skin retention and maintained skin integrity without irritation, suggesting its potential for further investigation.

This study found that baricitinib significantly reduced alopecia severity in JAK inhibitor-naïve patients compared to those previously treated with tofacitinib, indicating that switching JAK inhibitors can be safe and may be beneficial for selected patients with partial prior responses.

In this study, baricitinib was found to be effective and safe for treating severe alopecia areata, with significant hair regrowth observed in many patients by the third month of therapy and continued improvement by the twelfth month, despite mostly mild adverse events.

This study used a mouse model to enhance understanding of alopecia pathogenesis and suggested a therapeutic strategy for managing inflammation in EGFR-inhibitor therapy-induced folliculitis and cicatricial alopecia.

This review found that hair loss is common in women after bariatric surgery, linked to nutritional deficiencies and rapid weight loss, highlighting the need for further research and nutrient monitoring.

This narrative review explores how obesity, related diseases, and bariatric surgery can impact hair health and the hair development cycle, highlighting potential effects such as hair thinning and telogen effluvium.

This article discusses frontal fibrosing alopecia as a type of Lichen planopilaris marked by gradual hair loss at the front of the scalp but reports no new clinical results.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

Baricitinib helps regrow hair in severe alopecia areata, with results varying by initial hair loss severity and episode duration.

This study compared the adverse effects of baricitinib and methotrexate in treating severe alopecia areata and found baricitinib to have a better safety profile, though it was associated with increased cholesterol, triglyceride, and LDL levels.

This study reports that patients with severe alopecia areata who experienced sustained scalp regrowth while receiving continuous baricitinib treatment showed improvements in health-related quality of life and reductions in anxiety and depression symptoms.

This source reports that baricitinib significantly promotes hair regrowth in patients with severe alopecia areata, particularly those with a SALT score of 50 or higher, in clinical trials.